Ensign Peak Advisors
RYTM icon

Ensign Peak Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ensign Peak Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$412K Sell
3,709
-150
-4% -$13.6K ﹤0.01% 1045
2026
Q1 		$336K Hold
3,859
– – ﹤0.01% 1079
2025
Q4 		$413K Sell
3,859
-107,685
-97% -$11.4M ﹤0.01% 1005
2025
Q3 		$11.3M Buy
111,544
+93,885
+532% +$8.72M 0.02% 430
2025
Q2 		$1.12M Hold
17,659
– – ﹤0.01% 1179
2025
Q1 		$935K Hold
17,659
– – ﹤0.01% 1292
2024
Q4 		$989K Hold
17,659
– – ﹤0.01% 1325
2024
Q3 		$925K Hold
17,659
– – ﹤0.01% 1368
2024
Q2 		$725K Hold
17,659
– – ﹤0.01% 1474
2024
Q1 		$765K Sell
17,659
-891
-5% -$39K ﹤0.01% 1485
2023
Q4 		$853K Hold
18,550
– – ﹤0.01% 1471
2023
Q3 		$425K Buy
18,550
+2,350
+15% +$52.6K ﹤0.01% 1633
2023
Q2 		$267K Buy
+16,200
New +$292K ﹤0.01% 1724
2023
Q1 		– Sell
-108,562
Closed -$3.16M – 1785
2022
Q4 		$3.16M Buy
108,562
+97,392
+872% +$2.5M 0.01% 675
2022
Q3 		$274K Sell
11,170
-18,175
-62% -$338K ﹤0.01% 1751
2022
Q2 		$122K Buy
29,345
+24,255
+477% +$133K ﹤0.01% 1923
2022
Q1 		$59K Hold
5,090
– – ﹤0.01% 2104
2021
Q4 		$51K Buy
+5,090
New +$57.2K ﹤0.01% 2141
2021
Q3 		– Sell
-40,891
Closed -$801K – 1876
2021
Q2 		$801K Hold
40,891
– – ﹤0.01% 1494
2021
Q1 		$870K Buy
40,891
+19,718
+93% +$572K ﹤0.01% 1467
2020
Q4 		$629K Hold
21,173
– – ﹤0.01% 1553
2020
Q3 		$459K Buy
+21,173
New +$485K ﹤0.01% 1551

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ensign Peak Advisors's RYTM Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 3.9% in Q2 2026, selling an estimated $13.6K and leaving 3,709 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #1045.

Ensign Peak Advisors first reported a position in RYTM in Q3 2020 and has held it in 22 quarters since. The position peaked at $11.3M in Q3 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Ensign Peak Advisors held 3,709 shares of Rhythm Pharmaceuticals worth $412K as of Q2 2026.
  • Ensign Peak Advisors sold 150 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $13.6K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1045 holding.
  • Ensign Peak Advisors first reported a position in Rhythm Pharmaceuticals in Q3 2020 and has held it in 22 quarters since.
  • Ensign Peak Advisors's Rhythm Pharmaceuticals position peaked at $11.3M in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.